Erythropoietin Dose and Mortality in Hemodialysis Patients: Marginal Structural Model to Examine Causality
It has been previously reported that a higher erythropoiesis stimulating agent (ESA) dose in hemodialysis patients is associated with adverse outcomes including mortality; however the causal relationship between ESA and mortality is still hotly debated. We hypothesize ESA dose indeed exhibits a dire...
Main Authors: | Elani Streja, Jongha Park, Ting-Yan Chan, Janet Lee, Melissa Soohoo, Connie M. Rhee, Onyebuchi A. Arah, Kamyar Kalantar-Zadeh |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2016-01-01
|
Series: | International Journal of Nephrology |
Online Access: | http://dx.doi.org/10.1155/2016/6087134 |
Similar Items
-
Residual Urine Output and Mortality in a Prospective Hemodialysis Cohort
by: Amy S. You, et al.
Published: (2020-05-01) -
The Marginal Cost of Frailty Among Medicare Patients on Hemodialysis
by: John Sy, et al.
Published: (2020-03-01) -
Serum uric acid and mortality risk among maintenance hemodialysis patients
by: Inkyong Hur, et al.
Published: (2017-12-01) -
Obesity may be erythropoietin dose-saving in hemodialysis patients
by: Ghada M. El-Kannishy, et al.
Published: (2018-06-01) -
Use of Erythropoietin Dosing and Associated Factors in Hemodialysis Patients
by: Chung Yu-Chieh, et al.
Published: (2012)